Ethyl 3-(5-ethyl-1,2,4-oxadiazol-3-YL)benzoate
AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.